DNA B Pharmaceutical composition comprising interferon and DNA methylation inhibitor as an active ingredient for prevention or treatment of hepatitis virus B infection
The present invention relates to a pharmaceutical composition for the prevention and treatment of hepatitis B virus (HBV) infectious disease, which comprises an interferon and a DNA methylation inhibitor which induce the expression of TRIM22 protein as an active ingredient, The interferon of the present invention may be secreted during HBV infection to increase the expression of the antiviral protein TRIM22, and the DNA methylation inhibitor of the present invention may be used as an antimicrobial agent such as TRIM22, which HBV is epigenically regulated in order to avoid immune response of host cells The expression level of the TRIM22 protein by IFN can be significantly restored by inhibiting the methylation of the CpG (+71) islet of the gene promoter and 5'UTR so that the expression level of the TRIM22 protein by the IFN can be significantly recovered. The composition can be used to enhance the anti-HBV therapeutic effect of an interferon therapeutic agent conventionally used for HBV and to prevent the development of chronic B-type infection when infected with HBV You can suppress rows.본 발명은 TRIM22 단백질의 발현을 유도하는 인터페론(interferon) 및 DNA 메틸화 억제제를 유효성분으로 포함하는, B형 간염 바이러스(Hepatitis Virus B, HBV) 감염증 예방 및 치료용 약학적 조성물에 관한 것으로, 구체적으로 본 발명의 인터페론은 HBV 감염 시 분비되어 항바이러스 단백질인 TRIM22의 발현을 증가시킬 수 있고, 본 발명의 DNA 메틸화 억제제는 HBV가 숙주 세포의 면역 반응을 회피하기 위해 후성적(epigenetic)으로 조절하는 TRIM22 유전자 프로모터 및 5`UTR의 CpG(+71) 섬을 메틸화를 억제하여, IFN에 의한 TRIM22 단백질의 발현 수준이 유의적으로 회복할 수 있도록 하므로, 본 발명의 인터페론 및 DNA 메틸화 억제제를 포함하는 약학적 조성물은, HBV에 대하여 종래 사용되던 인터페론 치료제의 항-HBV 치료 효과를 증진시켜 HBV에 감염되었을 때 만성 B형 감염으로의 진행을 억제할 수 있다.
